EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Enanta Pharmaceuticals, Inc. (ENTA) had EBIT Margin of -69.07% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$17.16M |
|
$-13.09M |
|
-- |
|
$17.16M |
|
$29.01M |
|
$-11.85M |
|
$-1.23M |
|
$-13.08M |
|
$-13.08M |
|
$-13.09M |
|
$-13.09M |
|
$-13.09M |
|
$-13.09M |
|
$-11.85M |
|
$-10.34M |
|
29.04M |
|
29.04M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$178.41M |
|
$33.11M |
|
$136.29M |
|
$314.70M |
|
$46.44M |
|
-- |
|
$151.68M |
|
$198.12M |
|
$116.59M |
|
$116.59M |
|
$116.59M |
|
29.06M |
|
| Cash Flow Statement Financials | |
$-18.86M |
|
$-35.36M |
|
$56.84M |
|
$35.66M |
|
$38.29M |
|
$2.63M |
|
$7.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.84 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-69.07% |
|
|
EBIT Margin |
-69.07% |
-- |
|
-76.25% |
|
-76.29% |
|
$-19.01M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
2.19 |
|
41.06 |
|
-11.23% |
|
-11.23% |
|
-4.16% |
|
-11.23% |
|
$4.01 |
|
$-0.65 |
|
$-0.65 |
|